Overall Survival

Concept

---

Theoretically, Overall Survival (OS) is a time-to-event outcome measuring the duration from a predefined starting point, such as randomisation or treatment initiation, until death from any cause. It is regarded as the definitive clinical endpoint in oncology because it directly measures patient survival without requiring assumptions regarding disease progression or surrogate outcomes. The concept is founded on survival analysis and censoring theory and forms the principal endpoint for many clinical trials and health technology assessments.

Mathematically, Overall Survival is represented as a survival time variable subject to right censoring when patients remain alive at the end of follow-up or are lost to follow-up. Survival probabilities are estimated using non-parametric methods such as the Kaplan-Meier estimator or parametric survival models. Comparative analyses typically employ hazard ratios estimated using Cox proportional hazards regression, while health economic models frequently extrapolate survival using fitted parametric distributions.

In practice, Overall Survival is calculated from the date of randomisation, diagnosis or treatment initiation until the date of death from any cause. Patients who remain alive at the data cut-off are censored at their last known follow-up. In health economics, Overall Survival is a principal input for estimating life-years gained, quality-adjusted life years, healthcare resource utilisation and incremental cost-effectiveness of competing interventions.

Purpose

---

Used to quantify the survival benefit of healthcare interventions, supporting regulatory approval, comparative effectiveness research and health economic evaluation.

---

Mathematical Formulae

Primary Formula

OS = Tdeath ? Tstart

where Tstart is the predefined origin of follow-up (for example, randomisation or treatment initiation).

Supporting Formulae

Kaplan-Meier survival estimate:

?(t) = ?(1 ? d? / n?)

Hazard ratio:

HR = h?(t) / h?(t)

Hazard function:

h(t) = f(t) / S(t)

Restricted mean survival time:

RMST = ??^� S(t) dt

Related Mathematical Methods

• Kaplan-Meier Estimation
• Cox Proportional Hazards Model
• Parametric Survival Modelling
• Log-Rank Test
• Restricted Mean Survival Time
• Survival Analysis
• Censoring

---

Example

An oncology trial follows a patient who is randomised on 1 January 2025.

The patient dies on 1 July 2027.

Overall Survival:

OS = 30 months

If another patient remains alive at the analysis cut-off after 32 months of follow-up, the observation is right censored at 32 months and contributes survival information until that time.

---

Excel Implementation

Function	Example Formula	Health Economics Application
DATEDIF	=DATEDIF(StartDate,EndDate,"m")	Calculates overall survival time in months.
IF	=IF(DeathDate="",DATEDIF(StartDate,CutoffDate,"d"),DATEDIF(StartDate,DeathDate,"d"))	Calculates survival time while accounting for censored observations.
MEDIAN	=MEDIAN(SurvivalRange)	Calculates the observed median survival where complete observations are available.
COUNTIFS	=COUNTIFS(StatusRange,"Dead")	Counts survival events for trial reporting.
AVERAGE	=AVERAGE(SurvivalRange)	Summarises observed survival time, recognising that survival analysis methods are preferred for censored data.

---

VBA (Optional)

VBA can automate preparation of censored survival datasets, calculate survival times and generate inputs for Kaplan-Meier and parametric survival analyses.

---

Sources

• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.
• Cox DR. Regression Models and Life-Tables.
• Collett D. Modelling Survival Data in Medical Research.
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer. 2009.
• Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes.
• Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation.